Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure.
BACKGROUND: The calcium sensitizer levosimendan improves myocardial contractility in patients with heart failure, although its effects on inflammation and apoptosis are unknown. AIM: To examine the effects of levosimendan on markers of inflammation and apoptosis, over a period of 30 d following a 2...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2006
|
| _version_ | 1826288933640601600 |
|---|---|
| author | Trikas, A Antoniades, C Latsios, G Vasiliadou, K Karamitros, I Tousoulis, D Tentolouris, C Stefanadis, C |
| author_facet | Trikas, A Antoniades, C Latsios, G Vasiliadou, K Karamitros, I Tousoulis, D Tentolouris, C Stefanadis, C |
| author_sort | Trikas, A |
| collection | OXFORD |
| description | BACKGROUND: The calcium sensitizer levosimendan improves myocardial contractility in patients with heart failure, although its effects on inflammation and apoptosis are unknown. AIM: To examine the effects of levosimendan on markers of inflammation and apoptosis, over a period of 30 d following a 24 h infusion, in patients with heart failure. METHODS: Thirty four patients with severe heart failure were randomised to receive a 24 h infusion of levosimendan or placebo, in a double-blind trial. Haemodynamic evaluation and blood sampling were performed at baseline, 24 h, 30 h, 48 h, 7 d and 30 d after the end of the infusion. RESULTS: Seven patients (1 levosimendan, 6 placebo), were excluded during follow-up. In the remaining 27 patients, levosimendan decreased serum IL-6 and sFAS, 24 h after the infusion (p<0.01 and p<0.05 vs baseline), an effect sustained for 7-30 d. Serum TNF-alpha and sTNF-R1 were decreased between 48 h (p<0.01 vs baseline for both) and 7 d (p<0.05 vs baseline for sTNF-R1) after infusion. Serum sTNF-R2 was decreased at 24 h (p<0.05 vs baseline) and remained lower than baseline for at least 7 d (p<0.05). CONCLUSIONS: These findings indicate that levosimendan decreases the expression of proinflammatory cytokines, TNF-alpha receptors and sFAS, immediately after infusion, an effect which persists for 7-30 d. |
| first_indexed | 2024-03-07T02:21:13Z |
| format | Journal article |
| id | oxford-uuid:a3fa0eb2-5afa-480d-a789-35e7e35e9f1c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:21:13Z |
| publishDate | 2006 |
| record_format | dspace |
| spelling | oxford-uuid:a3fa0eb2-5afa-480d-a789-35e7e35e9f1c2022-03-27T02:30:48ZLong-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a3fa0eb2-5afa-480d-a789-35e7e35e9f1cEnglishSymplectic Elements at Oxford2006Trikas, AAntoniades, CLatsios, GVasiliadou, KKaramitros, ITousoulis, DTentolouris, CStefanadis, C BACKGROUND: The calcium sensitizer levosimendan improves myocardial contractility in patients with heart failure, although its effects on inflammation and apoptosis are unknown. AIM: To examine the effects of levosimendan on markers of inflammation and apoptosis, over a period of 30 d following a 24 h infusion, in patients with heart failure. METHODS: Thirty four patients with severe heart failure were randomised to receive a 24 h infusion of levosimendan or placebo, in a double-blind trial. Haemodynamic evaluation and blood sampling were performed at baseline, 24 h, 30 h, 48 h, 7 d and 30 d after the end of the infusion. RESULTS: Seven patients (1 levosimendan, 6 placebo), were excluded during follow-up. In the remaining 27 patients, levosimendan decreased serum IL-6 and sFAS, 24 h after the infusion (p<0.01 and p<0.05 vs baseline), an effect sustained for 7-30 d. Serum TNF-alpha and sTNF-R1 were decreased between 48 h (p<0.01 vs baseline for both) and 7 d (p<0.05 vs baseline for sTNF-R1) after infusion. Serum sTNF-R2 was decreased at 24 h (p<0.05 vs baseline) and remained lower than baseline for at least 7 d (p<0.05). CONCLUSIONS: These findings indicate that levosimendan decreases the expression of proinflammatory cytokines, TNF-alpha receptors and sFAS, immediately after infusion, an effect which persists for 7-30 d. |
| spellingShingle | Trikas, A Antoniades, C Latsios, G Vasiliadou, K Karamitros, I Tousoulis, D Tentolouris, C Stefanadis, C Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. |
| title | Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. |
| title_full | Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. |
| title_fullStr | Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. |
| title_full_unstemmed | Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. |
| title_short | Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. |
| title_sort | long term effects of levosimendan infusion on inflammatory processes and sfas in patients with severe heart failure |
| work_keys_str_mv | AT trikasa longtermeffectsoflevosimendaninfusiononinflammatoryprocessesandsfasinpatientswithsevereheartfailure AT antoniadesc longtermeffectsoflevosimendaninfusiononinflammatoryprocessesandsfasinpatientswithsevereheartfailure AT latsiosg longtermeffectsoflevosimendaninfusiononinflammatoryprocessesandsfasinpatientswithsevereheartfailure AT vasiliadouk longtermeffectsoflevosimendaninfusiononinflammatoryprocessesandsfasinpatientswithsevereheartfailure AT karamitrosi longtermeffectsoflevosimendaninfusiononinflammatoryprocessesandsfasinpatientswithsevereheartfailure AT tousoulisd longtermeffectsoflevosimendaninfusiononinflammatoryprocessesandsfasinpatientswithsevereheartfailure AT tentolourisc longtermeffectsoflevosimendaninfusiononinflammatoryprocessesandsfasinpatientswithsevereheartfailure AT stefanadisc longtermeffectsoflevosimendaninfusiononinflammatoryprocessesandsfasinpatientswithsevereheartfailure |